Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 100 entries
Sorted by: Best Match Show Resources per page
Genome Sequences of Three Cluster C Mycobacteriophages, Bipolarisk, Bread, and FudgeTart.

Microbiology resource announcements

Bowder DM, Gannon BW, Grint KJ, Iltz JT, Koch TM, Mahnke KS, Murnan BD, Osborn AM, Schreiber DM, Su GL, Troester JG, Doyle EL.
PMID: 31296672
Microbiol Resour Announc. 2019 Jul 11;8(28). doi: 10.1128/MRA.00290-19.

Three mycobacteriophages, Bipolarisk, Bread, and FudgeTart, were isolated from enriched soil samples found in Crete, NE. All three phages are lytic, belong to subcluster C1, and infect

Cite
Bowder DM, Gannon BW, Grint KJ, et al. Genome Sequences of Three Cluster C Mycobacteriophages, Bipolarisk, Bread, and FudgeTart. Microbiol Resour Announc. 2019;8(28)doi: 10.1128/MRA.00290-19.
Bowder, D. M., Gannon, B. W., Grint, K. J., Iltz, J. T., Koch, T. M., Mahnke, K. S., Murnan, B. D., Osborn, A. M., Schreiber, D. M., Su, G. L., Troester, J. G., & Doyle, E. L. (2019). Genome Sequences of Three Cluster C Mycobacteriophages, Bipolarisk, Bread, and FudgeTart. Microbiology resource announcements, 8(28), . https://doi.org/10.1128/MRA.00290-19
Bowder, Dane M, et al. "Genome Sequences of Three Cluster C Mycobacteriophages, Bipolarisk, Bread, and FudgeTart." Microbiology resource announcements vol. 8,28 (2019). doi: https://doi.org/10.1128/MRA.00290-19
Bowder DM, Gannon BW, Grint KJ, Iltz JT, Koch TM, Mahnke KS, Murnan BD, Osborn AM, Schreiber DM, Su GL, Troester JG, Doyle EL. Genome Sequences of Three Cluster C Mycobacteriophages, Bipolarisk, Bread, and FudgeTart. Microbiol Resour Announc. 2019 Jul 11;8(28). doi: 10.1128/MRA.00290-19. PMID: 31296672; PMCID: PMC6624755.
Copy Download .nbib Format: NLM
RE: Advanced Breast Cancer Definitions by Staging System Examined in the Breast Cancer Surveillance Consortium.

Journal of the National Cancer Institute

Pisano ED, Gatsonis C, Sparano J, Troester MA, Yaffe M, Cole E, Schnall MD.
PMID: 33783531
J Natl Cancer Inst. 2021 Jul 01;113(7):938-939. doi: 10.1093/jnci/djab055.

No abstract available.

Cite
Pisano ED, Gatsonis C, Sparano J, et al. RE: Advanced Breast Cancer Definitions by Staging System Examined in the Breast Cancer Surveillance Consortium. J Natl Cancer Inst. 2021;113(7):938-939doi: 10.1093/jnci/djab055.
Pisano, E. D., Gatsonis, C., Sparano, J., Troester, M. A., Yaffe, M., Cole, E., & Schnall, M. D. (2021). RE: Advanced Breast Cancer Definitions by Staging System Examined in the Breast Cancer Surveillance Consortium. Journal of the National Cancer Institute, 113(7), 938-939. https://doi.org/10.1093/jnci/djab055
Pisano, Etta D, et al. "RE: Advanced Breast Cancer Definitions by Staging System Examined in the Breast Cancer Surveillance Consortium." Journal of the National Cancer Institute vol. 113,7 (2021): 938-939. doi: https://doi.org/10.1093/jnci/djab055
Pisano ED, Gatsonis C, Sparano J, Troester MA, Yaffe M, Cole E, Schnall MD. RE: Advanced Breast Cancer Definitions by Staging System Examined in the Breast Cancer Surveillance Consortium. J Natl Cancer Inst. 2021 Jul 01;113(7):938-939. doi: 10.1093/jnci/djab055. PMID: 33783531; PMCID: PMC8266380.
Copy Download .nbib Format: NLM
Personal history of autoimmune disease and other medical conditions and risk of myelodysplastic syndromes.

Cancer epidemiology

Linabery AM, Roesler MA, Richardson M, Warlick ED, Nguyen PL, Cioc AM, Poynter JN.
PMID: 34995873
Cancer Epidemiol. 2022 Jan 05;76:102090. doi: 10.1016/j.canep.2021.102090. Epub 2022 Jan 05.

BACKGROUND: Autoimmune diseases and hematopoietic malignancies are known to cluster within individuals, suggesting intertwined etiologies. A limited number of studies have evaluated pre-existing medical conditions as risk factors for myelodysplastic syndromes (MDS). We evaluated associations between autoimmune disease and...

Cite
Linabery AM, Roesler MA, Richardson M, et al. Personal history of autoimmune disease and other medical conditions and risk of myelodysplastic syndromes. Cancer Epidemiol. 2022;76:102090doi: 10.1016/j.canep.2021.102090.
Linabery, A. M., Roesler, M. A., Richardson, M., Warlick, E. D., Nguyen, P. L., Cioc, A. M., & Poynter, J. N. (2022). Personal history of autoimmune disease and other medical conditions and risk of myelodysplastic syndromes. Cancer epidemiology, 76102090. https://doi.org/10.1016/j.canep.2021.102090
Linabery, Amy M, et al. "Personal history of autoimmune disease and other medical conditions and risk of myelodysplastic syndromes." Cancer epidemiology vol. 76 (2022): 102090. doi: https://doi.org/10.1016/j.canep.2021.102090
Linabery AM, Roesler MA, Richardson M, Warlick ED, Nguyen PL, Cioc AM, Poynter JN. Personal history of autoimmune disease and other medical conditions and risk of myelodysplastic syndromes. Cancer Epidemiol. 2022 Jan 05;76:102090. doi: 10.1016/j.canep.2021.102090. Epub 2022 Jan 05. PMID: 34995873.
Copy Download .nbib Format: NLM
Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non-Muscle-Invasive Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research

Damrauer JS, Roell KR, Smith MA, Sun X, Kirk EL, Hoadley KA, Benefield HC, Iyer G, Solit DB, Milowsky MI, Kim WY, Nielsen ME, Wobker SE, Dalbagni G, Al-Ahmadie HA, Olshan AF, Bochner BH, Furberg H, Troester MA, Pietzak EJ.
PMID: 34117034
Clin Cancer Res. 2021 Aug 15;27(16):4599-4609. doi: 10.1158/1078-0432.CCR-21-0205. Epub 2021 Jun 11.

PURPOSE: Improved risk stratification and predictive biomarkers of treatment response are needed for non-muscle-invasive bladder cancer (NMIBC). Here we assessed the clinical utility of targeted RNA and DNA molecular profiling in NMIBC.EXPERIMENTAL DESIGN: Gene expression in NMIBC samples was...

Cite
Damrauer JS, Roell KR, Smith MA, et al. Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non-Muscle-Invasive Bladder Cancer. Clin Cancer Res. 2021;27(16):4599-4609doi: 10.1158/1078-0432.CCR-21-0205.
Damrauer, J. S., Roell, K. R., Smith, M. A., Sun, X., Kirk, E. L., Hoadley, K. A., Benefield, H. C., Iyer, G., Solit, D. B., Milowsky, M. I., Kim, W. Y., Nielsen, M. E., Wobker, S. E., Dalbagni, G., Al-Ahmadie, H. A., Olshan, A. F., Bochner, B. H., Furberg, H., Troester, M. A., & Pietzak, E. J. (2021). Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non-Muscle-Invasive Bladder Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(16), 4599-4609. https://doi.org/10.1158/1078-0432.CCR-21-0205
Damrauer, Jeffrey S, et al. "Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non-Muscle-Invasive Bladder Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,16 (2021): 4599-4609. doi: https://doi.org/10.1158/1078-0432.CCR-21-0205
Damrauer JS, Roell KR, Smith MA, Sun X, Kirk EL, Hoadley KA, Benefield HC, Iyer G, Solit DB, Milowsky MI, Kim WY, Nielsen ME, Wobker SE, Dalbagni G, Al-Ahmadie HA, Olshan AF, Bochner BH, Furberg H, Troester MA, Pietzak EJ. Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non-Muscle-Invasive Bladder Cancer. Clin Cancer Res. 2021 Aug 15;27(16):4599-4609. doi: 10.1158/1078-0432.CCR-21-0205. Epub 2021 Jun 11. PMID: 34117034; PMCID: PMC8416390.
Copy Download .nbib Format: NLM
TP53 Pathway Function, Estrogen Receptor Status, and Breast Cancer Risk Factors in the Carolina Breast Cancer Study.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Hurson AN, Abubakar M, Hamilton AM, Conway K, Hoadley KA, Love MI, Olshan AF, Perou CM, Garcia-Closas M, Troester MA.
PMID: 34737209
Cancer Epidemiol Biomarkers Prev. 2022 Jan;31(1):124-131. doi: 10.1158/1055-9965.EPI-21-0661. Epub 2021 Nov 04.

BACKGROUND: TP53 and estrogen receptor (ER) both play essential roles in breast cancer development and progression, with recent research revealing cross-talk between TP53 and ER signaling pathways. Although many studies have demonstrated heterogeneity of risk factor associations across ER...

Cite
Hurson AN, Abubakar M, Hamilton AM, et al. TP53 Pathway Function, Estrogen Receptor Status, and Breast Cancer Risk Factors in the Carolina Breast Cancer Study. Cancer Epidemiol Biomarkers Prev. 2021;31(1):124-131doi: 10.1158/1055-9965.EPI-21-0661.
Hurson, A. N., Abubakar, M., Hamilton, A. M., Conway, K., Hoadley, K. A., Love, M. I., Olshan, A. F., Perou, C. M., Garcia-Closas, M., & Troester, M. A. (2022). TP53 Pathway Function, Estrogen Receptor Status, and Breast Cancer Risk Factors in the Carolina Breast Cancer Study. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 31(1), 124-131. https://doi.org/10.1158/1055-9965.EPI-21-0661
Hurson, Amber N, et al. "TP53 Pathway Function, Estrogen Receptor Status, and Breast Cancer Risk Factors in the Carolina Breast Cancer Study." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 31,1 (2022): 124-131. doi: https://doi.org/10.1158/1055-9965.EPI-21-0661
Hurson AN, Abubakar M, Hamilton AM, Conway K, Hoadley KA, Love MI, Olshan AF, Perou CM, Garcia-Closas M, Troester MA. TP53 Pathway Function, Estrogen Receptor Status, and Breast Cancer Risk Factors in the Carolina Breast Cancer Study. Cancer Epidemiol Biomarkers Prev. 2022 Jan;31(1):124-131. doi: 10.1158/1055-9965.EPI-21-0661. Epub 2021 Nov 04. PMID: 34737209.
Copy Download .nbib Format: NLM
Lung and extrathoracic cancer incidence among underground uranium miners exposed to radon progeny in the Příbram region of the Czech Republic: a case-cohort study.

Occupational and environmental medicine

Kelly-Reif K, Sandler DP, Shore D, Schubauer-Berigan M, Troester M, Nylander-French L, Richardson DB.
PMID: 34417337
Occup Environ Med. 2022 Feb;79(2):102-108. doi: 10.1136/oemed-2021-107392. Epub 2021 Aug 20.

OBJECTIVES: Radon is carcinogenic, but more studies are needed to understand relationships with lung cancer and extrathoracic cancers at low exposures. There are few studies evaluating associations with cancer incidence or assessing the modifying effects of smoking.METHODS: We conducted...

Cite
Kelly-Reif K, Sandler DP, Shore D, et al. Lung and extrathoracic cancer incidence among underground uranium miners exposed to radon progeny in the Příbram region of the Czech Republic: a case-cohort study. Occup Environ Med. 2021;79(2):102-108doi: 10.1136/oemed-2021-107392.
Kelly-Reif, K., Sandler, D. P., Shore, D., Schubauer-Berigan, M., Troester, M., Nylander-French, L., & Richardson, D. B. (2022). Lung and extrathoracic cancer incidence among underground uranium miners exposed to radon progeny in the Příbram region of the Czech Republic: a case-cohort study. Occupational and environmental medicine, 79(2), 102-108. https://doi.org/10.1136/oemed-2021-107392
Kelly-Reif, Kaitlin, et al. "Lung and extrathoracic cancer incidence among underground uranium miners exposed to radon progeny in the Příbram region of the Czech Republic: a case-cohort study." Occupational and environmental medicine vol. 79,2 (2022): 102-108. doi: https://doi.org/10.1136/oemed-2021-107392
Kelly-Reif K, Sandler DP, Shore D, Schubauer-Berigan M, Troester M, Nylander-French L, Richardson DB. Lung and extrathoracic cancer incidence among underground uranium miners exposed to radon progeny in the Příbram region of the Czech Republic: a case-cohort study. Occup Environ Med. 2022 Feb;79(2):102-108. doi: 10.1136/oemed-2021-107392. Epub 2021 Aug 20. PMID: 34417337; PMCID: PMC8760136.
Copy Download .nbib Format: NLM
Integrating biology and access to care in addressing breast cancer disparities: 25 years' research experience in the Carolina Breast Cancer Study.

Current breast cancer reports

Emerson MA, Reeder-Hayes KE, Tipaldos HJ, Bell ME, Sweeney MR, Carey LA, Earp HS, Olshan AF, Troester MA.
PMID: 33815665
Curr Breast Cancer Rep. 2020 Sep;12(3):149-160. doi: 10.1007/s12609-020-00365-0. Epub 2020 May 14.

PURPOSE OF REVIEW: To review research on breast cancer mortality disparities, emphasizing research conducted in the Carolina Breast Cancer Study, with a focus on challenges and opportunities for integration of tumor biology and access characteristics across the cancer care...

Cite
Emerson MA, Reeder-Hayes KE, Tipaldos HJ, et al. Integrating biology and access to care in addressing breast cancer disparities: 25 years' research experience in the Carolina Breast Cancer Study. Curr Breast Cancer Rep. 2020;12(3):149-160doi: 10.1007/s12609-020-00365-0.
Emerson, M. A., Reeder-Hayes, K. E., Tipaldos, H. J., Bell, M. E., Sweeney, M. R., Carey, L. A., Earp, H. S., Olshan, A. F., & Troester, M. A. (2020). Integrating biology and access to care in addressing breast cancer disparities: 25 years' research experience in the Carolina Breast Cancer Study. Current breast cancer reports, 12(3), 149-160. https://doi.org/10.1007/s12609-020-00365-0
Emerson, Marc A, et al. "Integrating biology and access to care in addressing breast cancer disparities: 25 years' research experience in the Carolina Breast Cancer Study." Current breast cancer reports vol. 12,3 (2020): 149-160. doi: https://doi.org/10.1007/s12609-020-00365-0
Emerson MA, Reeder-Hayes KE, Tipaldos HJ, Bell ME, Sweeney MR, Carey LA, Earp HS, Olshan AF, Troester MA. Integrating biology and access to care in addressing breast cancer disparities: 25 years' research experience in the Carolina Breast Cancer Study. Curr Breast Cancer Rep. 2020 Sep;12(3):149-160. doi: 10.1007/s12609-020-00365-0. Epub 2020 May 14. PMID: 33815665; PMCID: PMC8011652.
Copy Download .nbib Format: NLM
Hepatocyte growth factor pathway expression in breast cancer by race and subtype.

Breast cancer research : BCR

Jones GS, Hoadley KA, Olsson LT, Hamilton AM, Bhattacharya A, Kirk EL, Tipaldos HJ, Fleming JM, Love MI, Nichols HB, Olshan AF, Troester MA.
PMID: 34344422
Breast Cancer Res. 2021 Aug 03;23(1):80. doi: 10.1186/s13058-021-01460-5.

BACKGROUND: African American women have the highest risk of breast cancer mortality compared to other racial groups. Differences in tumor characteristics have been implicated as a possible cause; however, the tumor microenvironment may also contribute to this disparity in...

Cite
Jones GS, Hoadley KA, Olsson LT, et al. Hepatocyte growth factor pathway expression in breast cancer by race and subtype. Breast Cancer Res. 2021;23(1):80doi: 10.1186/s13058-021-01460-5.
Jones, G. S., Hoadley, K. A., Olsson, L. T., Hamilton, A. M., Bhattacharya, A., Kirk, E. L., Tipaldos, H. J., Fleming, J. M., Love, M. I., Nichols, H. B., Olshan, A. F., & Troester, M. A. (2021). Hepatocyte growth factor pathway expression in breast cancer by race and subtype. Breast cancer research : BCR, 23(1), 80. https://doi.org/10.1186/s13058-021-01460-5
Jones, Gieira S, et al. "Hepatocyte growth factor pathway expression in breast cancer by race and subtype." Breast cancer research : BCR vol. 23,1 (2021): 80. doi: https://doi.org/10.1186/s13058-021-01460-5
Jones GS, Hoadley KA, Olsson LT, Hamilton AM, Bhattacharya A, Kirk EL, Tipaldos HJ, Fleming JM, Love MI, Nichols HB, Olshan AF, Troester MA. Hepatocyte growth factor pathway expression in breast cancer by race and subtype. Breast Cancer Res. 2021 Aug 03;23(1):80. doi: 10.1186/s13058-021-01460-5. PMID: 34344422; PMCID: PMC8336233.
Copy Download .nbib Format: NLM
Initiation and adherence to adjuvant endocrine therapy among urban, insured American Indian/Alaska Native breast cancer survivors.

Cancer

Emerson MA, Achacoso NS, Benefield HC, Troester MA, Habel LA.
PMID: 33620753
Cancer. 2021 Jun 01;127(11):1847-1856. doi: 10.1002/cncr.33423. Epub 2021 Feb 23.

BACKGROUND: It has been shown that racial/ethnic disparities exist with regard to initiation of and adherence to adjuvant endocrine therapy (AET). However, the relationship among American Indian/Alaska Native (AIAN) individuals is poorly understood, particularly among those who reside in...

Cite
Emerson MA, Achacoso NS, Benefield HC, et al. Initiation and adherence to adjuvant endocrine therapy among urban, insured American Indian/Alaska Native breast cancer survivors. Cancer. 2021;127(11):1847-1856doi: 10.1002/cncr.33423.
Emerson, M. A., Achacoso, N. S., Benefield, H. C., Troester, M. A., & Habel, L. A. (2021). Initiation and adherence to adjuvant endocrine therapy among urban, insured American Indian/Alaska Native breast cancer survivors. Cancer, 127(11), 1847-1856. https://doi.org/10.1002/cncr.33423
Emerson, Marc A, et al. "Initiation and adherence to adjuvant endocrine therapy among urban, insured American Indian/Alaska Native breast cancer survivors." Cancer vol. 127,11 (2021): 1847-1856. doi: https://doi.org/10.1002/cncr.33423
Emerson MA, Achacoso NS, Benefield HC, Troester MA, Habel LA. Initiation and adherence to adjuvant endocrine therapy among urban, insured American Indian/Alaska Native breast cancer survivors. Cancer. 2021 Jun 01;127(11):1847-1856. doi: 10.1002/cncr.33423. Epub 2021 Feb 23. PMID: 33620753; PMCID: PMC8191495.
Copy Download .nbib Format: NLM
Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer.

Cancer research

Patel A, García-Closas M, Olshan AF, Perou CM, Troester MA, Love MI, Bhattacharya A.
PMID: 34711612
Cancer Res. 2022 Jan 01;82(1):25-35. doi: 10.1158/0008-5472.CAN-21-1207. Epub 2021 Oct 28.

Continuous risk of recurrence scores (CRS) based on tumor gene expression are vital prognostic tools for breast cancer. Studies have shown that Black women (BW) have higher CRS than White women (WW). Although systemic injustices contribute substantially to breast...

Cite
Patel A, García-Closas M, Olshan AF, et al. Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer. Cancer Res. 2021;82(1):25-35doi: 10.1158/0008-5472.CAN-21-1207.
Patel, A., García-Closas, M., Olshan, A. F., Perou, C. M., Troester, M. A., Love, M. I., & Bhattacharya, A. (2022). Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer. Cancer research, 82(1), 25-35. https://doi.org/10.1158/0008-5472.CAN-21-1207
Patel, Achal, et al. "Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer." Cancer research vol. 82,1 (2022): 25-35. doi: https://doi.org/10.1158/0008-5472.CAN-21-1207
Patel A, García-Closas M, Olshan AF, Perou CM, Troester MA, Love MI, Bhattacharya A. Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer. Cancer Res. 2022 Jan 01;82(1):25-35. doi: 10.1158/0008-5472.CAN-21-1207. Epub 2021 Oct 28. PMID: 34711612; PMCID: PMC8732329.
Copy Download .nbib Format: NLM
APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell-Mediated Antitumor Immune Responses.

Cancer immunology research

DiMarco AV, Qin X, McKinney BJ, Garcia NMG, Van Alsten SC, Mendes EA, Force J, Hanks BA, Troester MA, Owzar K, Xie J, Alvarez JV.
PMID: 34795033
Cancer Immunol Res. 2022 Jan;10(1):70-86. doi: 10.1158/2326-6066.CIR-21-0146. Epub 2021 Nov 18.

The APOBEC family of cytidine deaminases is one of the most common endogenous sources of mutations in human cancer. Genomic studies of tumors have found that APOBEC mutational signatures are enriched in the HER2 subtype of breast cancer and...

Cite
DiMarco AV, Qin X, McKinney BJ, et al. APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell-Mediated Antitumor Immune Responses. Cancer Immunol Res. 2021;10(1):70-86doi: 10.1158/2326-6066.CIR-21-0146.
DiMarco, A. V., Qin, X., McKinney, B. J., Garcia, N. M. G., Van Alsten, S. C., Mendes, E. A., Force, J., Hanks, B. A., Troester, M. A., Owzar, K., Xie, J., & Alvarez, J. V. (2022). APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell-Mediated Antitumor Immune Responses. Cancer immunology research, 10(1), 70-86. https://doi.org/10.1158/2326-6066.CIR-21-0146
DiMarco, Ashley V, et al. "APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell-Mediated Antitumor Immune Responses." Cancer immunology research vol. 10,1 (2022): 70-86. doi: https://doi.org/10.1158/2326-6066.CIR-21-0146
DiMarco AV, Qin X, McKinney BJ, Garcia NMG, Van Alsten SC, Mendes EA, Force J, Hanks BA, Troester MA, Owzar K, Xie J, Alvarez JV. APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell-Mediated Antitumor Immune Responses. Cancer Immunol Res. 2022 Jan;10(1):70-86. doi: 10.1158/2326-6066.CIR-21-0146. Epub 2021 Nov 18. PMID: 34795033.
Copy Download .nbib Format: NLM
Racial differences in breast cancer outcomes by hepatocyte growth factor pathway expression.

Breast cancer research and treatment

Jones GS, Hoadley KA, Benefield H, Olsson LT, Hamilton AM, Bhattacharya A, Kirk EL, Tipaldos HJ, Fleming JM, Williams KP, Love MI, Nichols HB, Olshan AF, Troester MA.
PMID: 35034243
Breast Cancer Res Treat. 2022 Jan 16; doi: 10.1007/s10549-021-06497-w. Epub 2022 Jan 16.

PURPOSE: Black women have a 40% increased risk of breast cancer-related mortality. These outcome disparities may reflect differences in tumor pathways and a lack of targetable therapies for specific subtypes that are more common in Black women. Hepatocyte growth...

Cite
Jones GS, Hoadley KA, Benefield H, et al. Racial differences in breast cancer outcomes by hepatocyte growth factor pathway expression. Breast Cancer Res Treat. 2022;doi: 10.1007/s10549-021-06497-w.
Jones, G. S., Hoadley, K. A., Benefield, H., Olsson, L. T., Hamilton, A. M., Bhattacharya, A., Kirk, E. L., Tipaldos, H. J., Fleming, J. M., Williams, K. P., Love, M. I., Nichols, H. B., Olshan, A. F., & Troester, M. A. (2022). Racial differences in breast cancer outcomes by hepatocyte growth factor pathway expression. Breast cancer research and treatment, . https://doi.org/10.1007/s10549-021-06497-w
Jones, Gieira S, et al. "Racial differences in breast cancer outcomes by hepatocyte growth factor pathway expression." Breast cancer research and treatment vol. (2022). doi: https://doi.org/10.1007/s10549-021-06497-w
Jones GS, Hoadley KA, Benefield H, Olsson LT, Hamilton AM, Bhattacharya A, Kirk EL, Tipaldos HJ, Fleming JM, Williams KP, Love MI, Nichols HB, Olshan AF, Troester MA. Racial differences in breast cancer outcomes by hepatocyte growth factor pathway expression. Breast Cancer Res Treat. 2022 Jan 16; doi: 10.1007/s10549-021-06497-w. Epub 2022 Jan 16. PMID: 35034243.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 100 entries